Abstract:Objectives EGFR testing is a mandatory step before targeted therapy for non-small cell lung cancer patients. Combining some quantifiable features to establish a predictive model of EGFR expression status, break the limitations of tissue biopsy. Materials and Methods We retrospectively analyzed 1074 patients of non-small cell lung cancer with complete reports of EGFR gene testing. Then manually segmented VOI, captured the clinicopathological features, analyzed traditional radiology features, and extracted radiomic, and deep learning features. The cases were randomly divided into training and test set. We carried out feature screening; then applied the light GBM algorithm, Resnet-101 algorithm, logistic regression to develop sole models, and fused models to predict EGFR mutation conditions. The efficiency of models was evaluated by ROC and PRC curves. Results We successfully established Model clinical , Model radiomic , Model CNN (based on clinical-radiology, radiomic and deep learning features respectively), Model radiomic+clinical (combining clinical-radiology and radiomic features), and Model CNN+radiomic+clinical (combining clinical-radiology, radiomic, and deep learning features). Among the prediction models, Model CNN+radiomic+clinical showed the highest performance, followed by Model CNN , and then Model radiomic+clinical . All three models were able to accurately predict EGFR mutation with AUC values of 0.751, 0.738, and 0.684, respectively. There was no significant difference in the AUC values between Model CNN+radiomic+clinical and Model CNN . Further analysis showed that Model CNN+radiomic+clinical effectively improved the efficacy of Model radiomic+clinical and showed better efficacy than Model CNN . The inclusion of clinical-radiology features did not effectively improve the efficacy of Model radiomic . Conclusions Either deep learning or radiomic signature-based models can provide a fairly accurate non-invasive prediction of EGFR expression status. The model combined both features effectively enhanced the performance of radiomic models and provided marginal enhancement to deep learning models. Collectively, fusion models offer a novel and more reliable way of providing the efficacy of currently developed prediction models, and have far-reaching potential for the optimization of noninvasive EGFR mutation status prediction methods.

VEGF-ERCNN: A deep learning-based model for prediction of vascular endothelial growth factor using ensemble residual CNN

An omics-driven computational model for angiogenic protein prediction: Advancing therapeutic strategies with Ens-deep-AGP

A Preliminary Study of Predicting Effectiveness of Anti-VEGF Injection Using OCT Images Based on Deep Learning.

Prediction of treatment outcome for branch retinal vein occlusion using convolutional neural network-based retinal fluorescein angiography

3D physiologically-informed deep learning for drug discovery of a novel vascular endothelial growth factor receptor-2 (VEGFR2)

Development and validation of CNN-MLP models for predicting anti-VEGF therapy outcomes in diabetic macular edema

Prediction of anti-vascular endothelial growth factor agent-specific treatment outcomes in neovascular age-related macular degeneration using a generative adversarial network

Efficient prediction of anticancer peptides through deep learning

Variational and Explanatory Neural Networks for Encoding Cancer Profiles and Predicting Drug Responses

Real-Time Prediction of Transarterial Drug Delivery Based on a Deep Convolutional Neural Network

Three-Dimensional Convolutional Neural Network-Based Prediction of Epidermal Growth Factor Receptor Expression Status in Patients With Non-Small Cell Lung Cancer

Potential inhibitors of VEGFR1, VEGFR2, and VEGFR3 developed through Deep Learning for the treatment of Cervical Cancer

Variational Autoencoder for Anti-Cancer Drug Response Prediction

DVS: Blood cancer detection using novel CNN-based ensemble approach

Application of Support Vector Machine Classification Model to Identification of Vascular Endothelial Growth Factor Receptor Inhibitors

Histopathology Based AI Model Predicts Anti-Angiogenic Therapy Response in Renal Cancer Clinical Trial

Deep Learning-based Prediction of Stress and Strain Maps in Arterial Walls for Improved Cardiovascular Risk Assessment

Deep Learning Prediction of Response to Anti-VEGF among Diabetic Macular Edema Patients: Treatment Response Analyzer System (TRAS)

Deep learning for predicting epidermal growth factor receptor mutations of non-small cell lung cancer on PET/CT images

Deep learning for automatic prediction of early activation of treatment naïve non-exudative MNVs in AMD

Prediction of angiogenesis in extrahepatic cholangiocarcinoma using MRI-based machine learning